Oesophageal histology in long term users of non-steroidal anti-inflammatory drugs

A S Taha, S Dahill, I Nakshabendi, F D Lee, R D Sturrock, R I Russell

Abstract

Aims—To study the oesophageal histological changes in long term users of non-steroidal anti-inflammatory drugs (NSAIDs) compared with patients not receiving these drugs.

Methods—Ninety eight patients were studied, 53 of whom had taken NSAIDs for three years; 45 had not. Oesophageal biopsy specimens were taken from healthy-looking mucosa in the lower third of oesophagus. The papillary length, the thickness of the basal cell layer, and the intensity of cells infiltrating the epithelium were all assessed blind.

Results—The NSAID group included four (7%) cases of papillary elongation and two (4%) cases of basal cell hyperplasia, compared with 13 (29%; p < 0.01) and eight (18%; p < 0.02), respectively, in patients not taking NSAIDs. The total histological scores were also lower in patients treated with NSAIDs.

Conclusion—Long term NSAID users have fewer oesophageal histological abnormalities than patients not receiving NSAIDs. Macroscopic damage related to NSAID use is, therefore, unlikely to require pre-existing histological oesophageitis for its development.

(J Clin Pathol 1994;47:705–708)

Mucosal inflammation has always been the focus of attention of both clinicians and pathologists alike because of its association with subsequent complications such as ulceration. Indeed, inflammation and ulceration are increasingly being accepted as two points in a disease spectrum with a common pathogenetic mechanism. There are several examples to support this, including inflammatory bowel disease, chronic gastritis, and duodenitis.1,2

Non-steroidal anti-inflammatory drugs (NSAIDs) remain among the most widely used group of drugs worldwide, and their side-effects could involve any part of the gastrointestinal tract.3 Histopathological changes related to NSAIDs in the stomach,4 duodenum,5 and the small and large intestine6,7 have been well documented, but very little is known about their effect on the oesophagus. This paper aims to rectify that by comparing a group of long term NSAID users with a group not taking these drugs.

Methods

Patients, aged 18 years or over, were recruited from the rheumatology and gastroenterology outpatient clinics. NSAIDs had to have been taken for at least four weeks before endoscopy. Patients not taking NSAIDs had to have an indication for endoscopy, such as upper abdominal complaints, because of ethical considerations. This was not the case in patients taking NSAIDs because of the known risk of asymptomatic damage in such a group.3 Patients were excluded if they had taken anti-ulcer drugs or vasodilators within four weeks of endoscopy, because of the effect of the former on acid secretion, and the potential of the latter to increase gastro-oesophageal reflux. Patients were also excluded if they had local oesophageal or systemic malignancy, a history of Crohn’s disease, or previous upper gastrointestinal surgery, because of the effect of these factors on oesophageal histology.

Informed consent was obtained and patients were endoscoped after an overnight fast. Diazepam or midazolam, 3–10 mg, were given intravenously for sedation.

In a preliminary assessment we found that the histological features of erosive or ulcerative oesophageal lesions in NSAID users were identical with those of non-users, although the neighbouring mucosa was less likely to look histologically inflamed in NSAID users. In the current study an average of two biopsy specimens were therefore taken from healthy-looking mucosa in the lower third of oesophagus, about 3 cm proximal to the cardia, and fixed in a standard solution of formol-saline. This is the area most likely to be affected by gastro-oesophageal reflux and by NSAID-related endoscopic damage.8 Two gastric antral biopsy specimens were also taken to test Helicobacter pylori by culture and histology.

The oesophageal histological findings (figs 1 and 2) were graded on a four point scale: 0, no lesion or normal; 1, very mild or possible; 2, a definite mild or moderate lesion; and 3, a severe lesion. The following features were studied.

Papillary elongation: normal length was up to 60% of the distance between the basal layer and the luminal surface.

Basal cell hyperplasia: a single layer was considered to be normal, and a definite abnormality was represented by at least two layers.

Cells in the epithelium: grade 0 was equivalent to the total absence of eosinophils or polymorphs; grade 1, less than five cells in the whole biopsy specimen; and grade 3, more
Results

Ninety eight patients were studied, 53 of whom were taking NSAIDs. Their clinical characteristics are shown in table 1. There were no significant differences in the age distribution, male:female ratio, smoking or drinking habits between the two groups. However, there were fewer patients with abdominal complaints in the NSAID group. This is because of the inclusion criteria that permitted entry into the study of asymptomatic NSAID users. Despite this difference, both groups had comparable numbers of peptic lesions, which were more likely to be found in the stomach of patients taking NSAIDs.

The types of NSAIDs used are shown in table 2. Most agents are known for their potent antiarthritic and ulcerogenic potentials. They were all taken in therapeutic doses for a median duration of three years.

Figure 3 gives the overall oesophageal histological scores as well as those of the three major histological features: papillary elongation; basal cell hyperplasia; and the infiltrative cell count. The differences between the two groups became more obvious when a line was drawn to separate the abnormal from the normal scores. Patients not taking NSAIDs included more cases with abnormal scores, especially with respect to papillary elongation

Table 2 Types of NSAID used

<table>
<thead>
<tr>
<th>Agent</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indomethacin</td>
<td>10</td>
</tr>
<tr>
<td>Naproxen</td>
<td>8</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>6</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>5</td>
</tr>
<tr>
<td>Piroxicam</td>
<td>4</td>
</tr>
<tr>
<td>Others*</td>
<td>20</td>
</tr>
<tr>
<td>Total</td>
<td>53</td>
</tr>
</tbody>
</table>

* Two to three patients per one of the following: azapropazone, etodolac, fenbufen, flurbiprofen, ibuprofen, nabumetone, sulindac, and tenoxicam.

Statistical analyses included the $\chi^2$ test and Fisher's exact test, where appropriate. All biopsy specimens carried code numbers, and all assessments were conducted blind.

Table 1 Patients' characteristics and demographic details

<table>
<thead>
<tr>
<th></th>
<th>Receiving NSAIDs: (n = 53)</th>
<th>No NSAIDs: (n = 45)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>13</td>
<td>19</td>
</tr>
<tr>
<td>Women</td>
<td>40</td>
<td>26</td>
</tr>
<tr>
<td>Age (years), median</td>
<td>58</td>
<td>52</td>
</tr>
<tr>
<td>(interquartile ranges)</td>
<td>(49-65)</td>
<td>(45-63)</td>
</tr>
<tr>
<td>Smokers</td>
<td>26</td>
<td>31</td>
</tr>
<tr>
<td>Drinkers</td>
<td>16</td>
<td>18</td>
</tr>
<tr>
<td>Abdominal complaints</td>
<td>29</td>
<td>45</td>
</tr>
<tr>
<td>Oesophageal erythema</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Gastric ulcers</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Duodenal ulcers</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>Gastric H pylori</td>
<td>31</td>
<td>36</td>
</tr>
</tbody>
</table>
Effect on the oesophagus

The abnormal sources tended to be more severe in the absence of NSAIDs as shown in the total scores scatterogram. It is also worth noting that a sizeable number of subjects with papillary elongation, regardless of NSAID intake, were smokers (16/17; 94%), associated with gastric H. pylori infection (15/17; 88%), and had a total of seven duodenal ulcers (7/17; 41%). Also, of 10 patients with basal cell hyperplasia, in the presence or absence of NSAID use, seven (70%) were smokers, seven (70%) had gastric H. pylori infection, but no duodenal ulcers were found in this group.

Discussion

This study shows that long term NSAID intake is associated with fewer oesophageal histological abnormalities, especially those related to papillary elongation and basal cell hyperplasia. The latter two abnormalities are also associated with smoking and with the presence of gastric H. pylori, regardless of NSAID intake.

The explanation for the above findings may be facilitated by considering the mechanisms that are known to influence the function and integrity of the oesophageal mucosa, and their possible interaction with NSAIDs. These consist mainly of factors that contribute to gastro-oesophageal reflux, including malfunction of the lower oesophageal sphincter, excess gastric contents (especially acid), poor gastric emptying, smoking and drugs, as well as other intrinsic oesophageal factors such as narrowing and poor motility. They all have in common prolonged exposure of the mucosa to the various injurious agents.

Acute exposure to NSAIDs is known to stimulate gastric acid secretion, and three years into this study it is not clear whether this applies to long term NSAID intake.

Another factor that needs to be considered is the interaction between NSAIDs and prostaglandin E₂ (PGE₂). Oesophagitis is associated with a local increase in the activity of PGE₂. Although such an increase could simply be due to infection itself, some workers believe that PGE₂ has a pro-inflammatory effect in the oesophagus. Acetylcholine, known to increase the lower oesophageal sphincter pressure, is suppressed by PGE₂ which, as a result, relaxes the lower oesophageal sphincter and might encourage gastro-oesophageal reflux. The inhibition of PGE₂ by NSAIDs could, at least in theory, decrease gastro-oesophageal reflux with its histological consequences. Papillary elongation and basal cell hyperplasia are known features of gastro-oesophageal reflux. Their low prevalence in our NSAID group could be due to the reduction of gastro-oesophageal reflux, or the absence of the hypertrophic activity of PGE₂ already inhibited by NSAIDs.

Although the above mechanisms might explain the relative normality of the oesophageal histology in chronic NSAID users, this does not necessarily imply that NSAIDs are protective to the oesophagus, as suggested by earlier experimental data, because of the following. Firstly, an increasing number of studies show oesophageal endoscopic damage related to NSAIDs even in healthy volunteers with normal findings on pretreatment endoscopy. Secondly, NSAIDs are generally acidic molecules with a pK between 4 and 5, being relatively lipid soluble at low pH. In the presence of gastro-oesophageal reflux, when the pH of the distal oesophagus is less than 4, these drugs may enter the oesophageal mucosal cells, with direct toxic effects. Thirdly, the previous experimental models that showed indomethacin associated decreases in mucosal injury have recently been challenged by workers who eliminated the effect of extramucosal factors. The latter have suggested that a PGE₂ analogue did not worsen cellular oesophagitis at low doses, and when higher antisecretory doses were used some improvement was noted in the degree of oesophagitis.

Our finding of an association between smoking and papillary elongation can be explained by the inhibitory effect of smoking on the lower oesophageal sphincter which in turn contributes to gastro-oesophageal reflux. We cannot, however, explain the apparent association between oesophageal papillary elongation and gastric H. pylori. To our knowledge, this has not been reported before, and the possibility of H. pylori related interference with gastric motility, which in turn might increase gastro-oesophageal reflux, cannot be excluded.

In conclusion, long term NSAID use is associated with a lower prevalence of histological abnormalities in the oesophagus. It is not, therefore, clear whether prior histological oesophagitis is essential for the development of NSAID related macroscopic damage in the oesophagus.

We thank Mrs Ruth Simpson for her secretarial assistance and Miss Pamela Boothman for her help with H pylori cultures.

Oesophageal histology in long term users of non-steroidal anti-inflammatory drugs.

A S Taha, S Dahill, I Nakshabendi, F D Lee, R D Sturrock and R I Russell

doi: 10.1136/jcp.47.8.705

Updated information and services can be found at:
[http://jcp.bmj.com/content/47/8/705](http://jcp.bmj.com/content/47/8/705)

**Email alerting service**

_These include:_

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)